Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $84.15 | Total: $420.75 |
| 1 | 10 | $71.28 | Total: $712.80 |
| 1 | 25 | $60.39 | Total: $1,509.75 |
| 1 | 50 | $51.48 | Total: $2,574.00 |
| 1 | 100 | $44.55 | Total: $4,455.00 |
Overview
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition to immune activation and antitumor activity.
Chemical Properties
| Molecular Formula | C144H230N40O50 |
| Molecular Weight | 3321.61 |
| CAS Numbers | 38216-54-5 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C([C@@](C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])([H])N([H])C([C@](C([H])([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C(N([H])[H])=O)([H])N([H])C([C@@]([C@@](C([H])([H])[H])([H])C([H])([H])C([H])([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C(O[H])=O)([H])N([H])N([H])[H])=O)=O)=O)=O)=O)N1[C@@](C(N([H])[C@](C(C([C@@](C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C(N([H])[H])=O)([H])N([H])C([C@@]([C@@](C([H])([H])[H])([H])O[H])([H])N([H])C([C@@](C(C([H])([H])[H])([H])C([H])([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C([H])([H])N([H])C(N([H])[H])=N[H])([H])N([H])C([C@@](C([H])([H])C2=C([H])C([H])=C([H])C([H])=C2[H])([H])N([H])C(C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])N([H])[C@@](C(N([H])[C@](C([H])([H])O[H])([H])C(N([H])[C@@](C(N([H])[C@](C([H])([H])O[H])([H])C(N([H])[C@@](C(N([H])[C@@](C(N([H])[C@@](C([H])=O)([H])C([H])([H])O[H])=O)([H])C([H])([H])C(N([H])[H])=O)=O)([H])[C@@](C([H])([H])[H])([H])O[H])=O)=O)([H])C([H])([H])C([H])([H])C(O[H])=O)=O)=O)([H])C([H])([H])C3=C([H])C([H])=C([H])C([H])=C3[H])([H])N([H])C([C@@](C([H])([H])C4=C([H])C([H])=C([H])C([H])=C4[H])([H])N([H])C([C@@](C([H])([H])O[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C(O[H])=O)([H])N([H])C([C@@](C([H])([H])O[H])([H])N([H])C([C@@]([C@@](C([H])([H])[H])([H])O[H])([H])N([H])C([C@@](C([H])([H])C(N([H])[H])=O)([H])N([H])C([C@@](C([H])([H])O[H])([H])N([H])[H])=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)([H])C([H])([H])[H])=O)([H])C([H])([H])C([H])([H])C1([H])[H].CC(O)=O |
Storage and Handling
0C Short Term, -20C Long Term
References
Pottayil G Sasikumar, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18[6] 1081-1091.